Oral Proteins & Peptides Market – Trends Forecast Till 2030

Market Snapshot

Market Overview

The global Oral Proteins & Peptides Market size was estimated at USD 7,350 million in 2023 and is projected to reach USD 33,318.8 million in 2030 at a CAGR of 24.10 % during the forecast period 2024-2030.

The oral proteins and peptides market refer to the development and utilization of proteins and peptides delivered orally as therapeutic agents or nutritional supplements. These biomolecules are critical in various medical and healthcare applications, offering solutions for metabolic disorders, malnutrition, and chronic diseases. The market is gaining prominence as the demand for non-injection-based treatments increases, making oral protein and peptide formulations an attractive alternative to conventional injectable therapies. This segment benefits from advances in drug delivery technologies, allowing for better absorption and efficacy of orally administered proteins and peptides.

The market scope is vast, covering a wide range of applications, including healthcare, sports nutrition, and clinical nutrition. In healthcare, oral proteins and peptides are utilized for treating diseases such as diabetes, cancer, and gastrointestinal disorders, while in sports and fitness, they are used to support muscle growth and recovery. The rising awareness of the benefits of proteins and peptides in promoting overall health and well-being has expanded their reach beyond medical use into general wellness. With increasing consumer interest in functional foods and supplements, the market for oral proteins and peptides is expected to see continued growth across various sectors.

Several trends are influencing the oral proteins and peptides market, including the growing preference for oral drug delivery systems over injectable alternatives, advancements in peptide synthesis, and the rising adoption of personalized medicine. The development of new peptide-based drugs, combined with innovations in encapsulation technologies to enhance bioavailability, has significantly boosted the market. Additionally, the rising consumer demand for plant-based and natural protein sources is prompting the development of alternative oral protein formulations that cater to dietary preferences and vegan lifestyles.

The key drivers of the oral proteins and peptides market include the increasing prevalence of chronic diseases, the growing demand for dietary supplements, and the technological advancements in oral protein delivery systems. With a rising global focus on preventative healthcare and healthier lifestyles, there is a surge in the use of protein and peptide-based products for both therapeutic and nutritional purposes. Additionally, the expansion of the pharmaceutical and biotechnology industries, along with the increasing investments in research and development, continues to fuel innovation and market growth in this segment.

Delvens Industry Expert's Standpoint

Experts in the Oral Proteins & Peptides Market highlight several key trends driving growth and innovation. The oral proteins and peptides market is expanding due to the growing demand for non-injection-based therapies and nutritional supplements. These biomolecules are increasingly used in healthcare for treating chronic diseases, in sports nutrition for muscle growth, and in general wellness. Advancements in drug delivery technologies, better absorption methods, and innovations in peptide synthesis are driving the market, along with the rising preference for plant-based and natural protein sources. Key factors such as the increasing prevalence of chronic conditions, the demand for dietary supplements, and ongoing research in oral protein delivery systems are fuelling market growth across various sectors.

Market Portfolio

Key Findings

• The glucagon-like peptide-1 (GLP-1) receptor agonist segment led the market by drug class. The drug class includes glycine-proline-glutamate (GPE) analogues, GLP-1 receptor agonists, guanylate cyclase-C agonists, calcineurin-inhibitor immunosuppressants, calcitonin gene-related peptide (CGRP) receptor antagonists, and others. The GLP-1 receptor agonist class accounted for the largest market share, with drugs designed to mimic the incretin hormone GLP-1. Initially used for type 2 diabetes mellitus, these drugs have gained prominence in managing obesity and overweight conditions as well.

• By end user, home care settings are projected to experience the highest growth. The oral proteins and peptides market is divided into home care settings, long-term care facilities, and hospitals & specialty clinics. In 2023, the home care settings segment is expected to register the highest compound annual growth rate (CAGR). This growth is driven by increasing awareness, ease of use, and the effectiveness of these drugs in treating conditions like diabetes, gastrointestinal disorders (e.g., IBD and constipation), and central nervous system disorders. Additionally, studies have shown that patients are more compliant with oral medication when administered in home care settings.

• The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America region is projected to hold the largest market share. Factors such as Increasing prevalence of chronic diseases, growing geriatric population, rising demand for non-injection therapies, advancements in drug delivery technologies, growing consumer awareness about health and wellness, expanding healthcare infrastructure, increased focus on personalized medicine, rising adoption of functional foods and dietary supplements, technological innovations in peptide synthesis, high patient compliance with oral administration have triggered the Oral Proteins & Peptides Market in the region.

Regional Analysis

North America to Dominate the Market

• The U.S. is at the forefront of the North American oral proteins and peptides market, fuelled by rising awareness of their benefits and a growing aging population. Furthermore, improvements in healthcare infrastructure and a strong focus on innovative therapies are key factors supporting the market's expansion in the U.S.
• The Asia-Pacific region is expected to witness the highest growth rate between 2021 and 2028, fuelled by the rising demand for effective drugs and cutting-edge technologies. Moreover, the region's expanding healthcare infrastructure and an increasing emphasis on enhancing access to innovative treatments are key factors driving market growth.

Competitive Landscape

• Novo Nordisk A/S
• AbbVie Inc.
• Pfizer Inc.
• Bausch Health Companies Inc.
• Chiesi Farmaceutici S.p.A.
• Acadia Pharmaceuticals Inc.
• Aurinia Pharmaceuticals Inc.
• Merck & Co., Inc.
• Johnson & Johnson Services, Inc.
• SWK Holdings
• R-Pharm JSC
• Entera Bio Ltd.
• Proxima Concepts
• AstraZeneca PLC
• Regor Therapeutics Group
• Terns Pharmaceuticals, Inc.
• Structure Therapeutics
• Viking Therapeutics
• Protagonist Therapeutics Inc.
• Rani Therapeutics
• Carmot Therapeutics, Inc.
• Zealand Pharma
• Sciwind Biosciences Co., Ltd.
• Jiangsu Hengrui Pharmaceuticals Co., Ltd

Recent Developments

• In September 2023, EnteraBio entered into a research collaboration agreement with OPKO Biologics, Inc. As part of the agreement, OPKO will supply its proprietary long-acting GLP-2 peptide and select Oxyntomodulin analogs to develop oral tablet formulations. This collaboration aims to advance innovative treatments for various medical conditions.

• In April 2023, Chiesi Farmaceutici S.p.A. acquired Amryt Pharma, a biopharmaceutical company focused on developing treatments for rare diseases. One of Amryt Pharma's prominent products is Mycapssa (octreotide capsules), which offers a new treatment option for acromegaly and neuroendocrine tumors, strengthening Chiesi's portfolio in the rare disease therapeutic space.

• In October 2022, Pfizer completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd., the developer of NURTEC ODT (rimegepant), a novel oral peptide therapy for migraine. This acquisition allowed Pfizer to expand its portfolio of innovative treatments for neurological conditions, especially for acute treatment and prevention of episodic migraines in adults.

• In December 2023, Pfizer received approval from Health Canada for NURTEC ODT (rimegepant) to treat acute migraines. This approval further extends the reach of the oral peptide, positioning it as an essential treatment option for patients suffering from episodic migraines and reinforcing Pfizer’s presence in the migraine treatment market.

Reasons to Acquire

• Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
• Gain authentic and granular data access for the Oral Proteins & Peptides Market to understand the trends and the factors involved in changing market situations.
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope